Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hepatitis
  Free Subscription

Articles published in
Vaccine
    February 2024
  1. KOCHHAR S, Assis DN, Mack C, Izurieta HS, et al
    Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024.
    >> Share

    January 2024
  2. SANTORO PE, Paladini A, Borrelli I, Amantea C, et al
    Vaccine-preventable diseases: Immune response in a large population of healthcare students.
    Vaccine. 2024 Jan 20:S0264-410X(24)00049-5. doi: 10.1016/j.vaccine.2024.
    >> Share

    December 2023
  3. DIONNE M, Sauvageau C, Kiely M, Dahhou M, et al
    School-based vaccination program against HPV and Hepatitis B: A longitudinal analysis of vaccine coverage between 2015 and 2021 in Quebec.
    Vaccine. 2023 Dec 2:S0264-410X(23)01419-6. doi: 10.1016/j.vaccine.2023.
    >> Share

    September 2023
  4. SANADA T, Oda Y, Ohashi C, Isotani K, et al
    Hybrid large hepatitis B surface protein composed of two viral genotypes C and D induces strongly cross-neutralizing antibodies.
    Vaccine. 2023 Sep 20:S0264-410X(23)01096-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  5. BIRNBAUM JA, Guttman D, Parulekar M, Omarufilo F, et al
    Eliminating hepatitis B vaccination disparities for West African immigrants.
    Vaccine. 2023 Sep 3:S0264-410X(23)01012-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  6. SUSARLA SK, Gupta M, Uttam KG, Palkar S, et al
    Immunogenicity and safety of Havisure(TM) vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
    Vaccine. 2023 Sep 1:S0264-410X(23)01050-2. doi: 10.1016/j.vaccine.2023.
    >> Share

    August 2023
  7. MAKI Y, Edo N, Mizuguchi M, Ikeda M, et al
    Impact of frequency and duration of freeze-dried inactivated tissue culture hepatitis A vaccine (Aimmugen(R)) vaccination on antibody titers; a japanese cross-sectional study.
    Vaccine. 2023 Aug 22:S0264-410X(23)00962-3. doi: 10.1016/j.vaccine.2023.
    >> Share

    July 2023
  8. DAS SK, Khan J
    Timeliness in the uptake of hepatitis B birth dose among Indian children under age five: A population-based study.
    Vaccine. 2023 Jul 17:S0264-410X(23)00827-7. doi: 10.1016/j.vaccine.2023.
    >> Share

    June 2023
  9. SHENG Y, Li Z, Lin X, Ma Y, et al
    The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Vaccine. 2023 Jun 28:S0264-410X(23)00759-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  10. FUKUSHIMA S, Kiyohara T, Nakano T, Tada Y, et al
    Delaying the third dose of Japanese aluminum-free hepatitis A vaccine Aimmugen elicits effective immune responses against hepatitis A in adults.
    Vaccine. 2023 Jun 21:S0264-410X(23)00723-5. doi: 10.1016/j.vaccine.2023.
    >> Share

    May 2023
  11. VESIKARI T, Langley JM, Spaans JN, Petrov I, et al
    The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine.
    Vaccine. 2023 May 11:S0264-410X(23)00528-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  12. CHOI Y, Lee GS, Li S, Lee JW, et al
    Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques.
    Vaccine. 2023 May 11:S0264-410X(23)00524-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  13. BERRY A, Kapelus D, Singh P, Groome M, et al
    ABO blood types, but not Secretor or Lewis blood types, influence strength of antibody response to Hepatitis B vaccine in Black South African children.
    Vaccine. 2023 May 9:S0264-410X(23)00465-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  14. TALBIRD SE, Anderson SA, Nossov M, Beattie N, et al
    Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis B in adults in the United States.
    Vaccine. 2023 May 3:S0264-410X(23)00414-0. doi: 10.1016/j.vaccine.2023.
    >> Share

    April 2023
  15. GIRNDT M, Houser P, Manllo-Karim R, Ervin JE, et al
    Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
    Vaccine. 2023 Apr 19:S0264-410X(23)00420-6. doi: 10.1016/j.vaccine.2023.
    >> Share

    March 2023
  16. DUGOVICH AM, Cox TH, Weeda ER, Garner SS, et al
    First hepatitis B vaccine uptake in neonates prior to and during the COVID-19 pandemic.
    Vaccine. 2023 Mar 27:S0264-410X(23)00333-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  17. WU L, Yang S, Huang Z, Liu J, et al
    Safety of concomitant administration of inactivated hepatitis A vaccine with other vaccines in children under 16 years old in post-marketing surveillance.
    Vaccine. 2023 Mar 3:S0264-410X(23)00226-8. doi: 10.1016/j.vaccine.2023.
    >> Share

    February 2023
  18. DENG HM, Romero N, Allard N, Rowe S, et al
    Uptake of perinatal immunoprophylaxis for infants born to women with a record of hepatitis B in Victoria (2009-2017).
    Vaccine. 2023 Feb 7:S0264-410X(23)00076-2. doi: 10.1016/j.vaccine.2023.
    >> Share

    January 2023
  19. TRICOU V, Eyre S, Ramjee M, Collini P, et al
    A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.
    Vaccine. 2023 Jan 19:S0264-410X(23)00007-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  20. DESCHANVRES C, Levieux K, Launay E, Huby AC, et al
    Non-immunization associated with increased risk of sudden unexpected death in infancy: A national case-control study.
    Vaccine. 2023;41:391-396.
    >> Share

  21. OVERBO J, Aziz A, Zaman K, Clemens J, et al
    Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial.
    Vaccine. 2023 Jan 2:S0264-410X(22)01599-7. doi: 10.1016/j.vaccine.2022.
    >> Share

    December 2022
  22. MOETLHOA B, Tjale M, Pretorius A, Hayeshi R, et al
    Rift Valley Fever vaccine strategies: Enhanced stability of RVF Clone 13.
    Vaccine. 2022 Dec 31:S0264-410X(22)01591-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  23. KIM TV, Pham TND, Le DH, Dao DVB, et al
    Significant gaps in hepatitis B vaccination in adults in Viet Nam: Important targets toward hepatitis B elimination by 2030.
    Vaccine. 2022 Dec 30:S0264-410X(22)01577-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  24. ZUBKOVA I, Zhao Y, Cui Q, Kachko A, et al
    Assessing the impact of hepatitis B immune globulin (HBIG) on responses to hepatitis B vaccine during co-administration.
    Vaccine. 2022 Dec 29:S0264-410X(22)01590-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  25. BOISSON A, Morgan CE, Stover A, Ngimbi P, et al
    Changes in hepatitis B vaccine perception in response to the COVID-19 pandemic: Development of the Shift in vaccine confidence (SVC) survey tool.
    Vaccine. 2022 Dec 16:S0264-410X(22)01542-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  26. MARIA FP, Maria BA, Dario RO, Paula AP, et al
    Effectiveness of the hepatitis B vaccine adjuvanted with AS04C in patients with biological therapies.
    Vaccine. 2022 Dec 13:S0264-410X(22)01521-3. doi: 10.1016/j.vaccine.2022.
    >> Share

    November 2022
  27. KIRTLAND KA, Raghunathan T, Patel Murthy B, Li J, et al
    Estimating vaccination coverage for routinely recommended vaccines among children aged 24months and adolescents aged 13 through 17years using data from immunization information systems in the United States.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01341.
    >> Share

  28. MORRILL JC, Peters CJ, Bettinger GE, Palermo PM, et al
    Rift Valley fever MP-12 vaccine elicits an early protective immune response in mice.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01339.
    >> Share

    October 2022
  29. RABE APJ, Costello P, Were JJ, Farrer A, et al
    The burden of selected vaccine-preventable diseases on the secondary care health system in England: Results from a five-year administrative healthcare dataset.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01263.
    >> Share

    September 2022
  30. KUIPER VP, van der Plas P, Hoogerwerf MA, Pieter R Koopman J, et al
    A comparison of two Fendrix hepatitis B vaccination schedules in patients with inflammatory bowel disease.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01100.
    >> Share

  31. FENG T, Li M, Zhang L, Li S, et al
    Immunity of two novel hepatitis C virus polyepitope vaccines.
    Vaccine. 2022 Sep 20. pii: S0264-410X(22)01115.
    >> Share

    August 2022
  32. ROMANO L, Tosti ME, Zanetti AR
    Beyond 30 years of universal anti-hepatitis B vaccination in Italy: Success and areas of improvement.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)00966.
    >> Share

    July 2022
  33. XIRIDOU M, Adam P, Meiberg A, Visser M, et al
    The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00847.
    >> Share

    May 2022
  34. OSTER G, Bornheimer R, Ottino K, Stevenson C, et al
    Adult immunization against hepatitis B: Does the number of jabs matter?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00534.
    >> Share

    April 2022
  35. BEULENS C, Raven SFH, van Jaarsveld CHM, van Loo I, et al
    Evaluation of a personalized, dose-sparing revaccination strategy in hepatitis B vaccine non-responders.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00470.
    >> Share

    March 2022
  36. BURNY W, Herve C, Caubet M, Yarzabal JP, et al
    Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00361.
    >> Share

  37. BREAKWELL L, Marke D, Kaiser R, Tejada-Strop A, et al
    Assessing the impact of the routine childhood hepatitis B immunization program and the need for hepatitis B vaccine birth dose in Sierra Leone, 2018.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00360.
    >> Share

    February 2022
  38. DE LUCA C, Schachner A, Heidl S, Hess M, et al
    Vaccination with a fowl adenovirus chimeric fiber protein (crecFib-4/11) simultaneously protects chickens against hepatitis-hydropericardium syndrome (HHS) and inclusion body hepatitis (IBH).
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00116.
    >> Share

    January 2022
  39. PITTET LF, Cox L, Freyne B, Germano S, et al
    Hepatitis B vaccine co-administration influences the heterologous effects of neonatal BCG vaccination in a sex-differential manner.
    Vaccine. 2022 Jan 29. pii: S0264-410X(22)00020.
    >> Share

    November 2021
  40. URUENA A, Badano MN, Bare P, Gonzalez J, et al
    Humoral and cellular immune memory response 12 years following single dose vaccination against hepatitis A in Argentinian children.
    Vaccine. 2021 Nov 24. pii: S0264-410X(21)01482.
    >> Share

  41. GORDEYCHUK I, Kyuregyan K, Kondrashova A, Bayurova E, et al
    Immunization with recombinant ORF2 p551 protein protects common marmosets (Callithrix jacchus) against homologous and heterologous hepatitis E virus challenge.
    Vaccine. 2021 Nov 23. pii: S0264-410X(21)01487.
    >> Share

  42. HAFNER-GIESSAUF H, Horn S, Schwantzer G, Sprenger-Mahr H, et al
    Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01474.
    >> Share

  43. THULUVA S, Matur R, Tsa K, Gv SR, et al
    A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEV(TM)) in 1-15 years-old healthy hepatitis A vaccine-naive children.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01326.
    >> Share

    October 2021
  44. NETANEL C, Ben-Aharon O, Ben-Ari Z, Chodick G, et al
    Evaluation of a universal hepatitis B vaccination program and antenatal screening for hepatitis B surface antigen: Results from a real-world study 2015-2016.
    Vaccine. 2021 Oct 20. pii: S0264-410X(21)01287.
    >> Share

  45. DANKWA EA, Donnelly CA, Brouwer AF, Zhao R, et al
    Estimating vaccination threshold and impact in the 2017-2019 hepatitis A virus outbreak among persons experiencing homelessness or who use drugs in Louisville, Kentucky, United states.
    Vaccine. 2021 Oct 19. pii: S0264-410X(21)01308.
    >> Share

  46. SRICHAN P, Thohinung U, Kodyee S, Apidechkul T, et al
    Vaccine serocoverage under the expanded program on immunization among hill tribe children in Thailand: A cross-sectional study.
    Vaccine. 2021 Oct 1. pii: S0264-410X(21)01264.
    >> Share

  47. KNUF M, Haas H, Garcia-Corbeira P, Turriani E, et al
    Hexavalent vaccines: What can we learn from head-to-head studies?
    Vaccine. 2021;39:6025-6036.
    >> Share

    September 2021
  48. KHAIMOVA R, Fischetti B, Cope R, Berkowitz L, et al
    Serological response with Heplisav-B(R) in prior Hepatitis B vaccine non-responders living with HIV.
    Vaccine. 2021 Sep 29. pii: S0264-410X(21)01251.
    >> Share

  49. HOFMEISTER MG, Weng MK, Thoroughman D, Thomasson ED, et al
    Prevalence of indications for adult hepatitis A vaccination among hepatitis A outbreak-associated cases, Three US States, 2016-2019.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01254.
    >> Share

  50. CHOWDHURY F, Akter A, Rahman Bhuiyan T, Tauheed I, et al
    A non-inferiority trial comparing two recombinant vaccines (Hepa-B vs. Engerix-B) for hepatitis B among adults in Dhaka, Bangladesh.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01222.
    >> Share

  51. ELBASHA EH, Choi Y, Daniels V, Goveia MG, et al
    Cost-effectiveness of routine catch-up hepatitis a vaccination in the United States: Dynamic transmission modeling study.
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01147.
    >> Share

    August 2021
  52. LEWIN BJ, Rodriguez J, Yang SJ, Tartof SY, et al
    Predictors of hepatitis A immunity in adults in California in order to better utilize hepatitis A vaccine.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01104.
    >> Share

  53. WANG R, Chen K, Wang Y, Liu C, et al
    Booster immunization improves the generation of T follicular helper (Tfh) cells specific to hepatitis B surface antigen (HBsAg) after prenatal HBsAg exposure.
    Vaccine. 2021 Aug 16. pii: S0264-410X(21)01040.
    >> Share

  54. JANSSEN RS, Bruxvoort K, Jacobsen SJ, Slezak J, et al
    Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)01015.
    >> Share

  55. GALOR I, Hartal M, Perry Markovich M, Avramovich E, et al
    Population seroprotection against hepatitis a virus in Israel 18 years after introduction of inactivated vaccine into the routine childhood vaccination schedule: Response letter, to letter to the editor.
    Vaccine. 2021;39:4777.
    >> Share

  56. HERZOG C
    Immune memory persistence is well documented for hepatitis A vaccines.
    Vaccine. 2021;39:4775-4776.
    >> Share

    July 2021
  57. DOI H, Kanto T
    Factors influencing the durability of hepatitis B vaccine responses.
    Vaccine. 2021 Jul 30. pii: S0264-410X(21)00876.
    >> Share

  58. GOSSET A, Diallo MY, Betsem E, Schaeffer L, et al
    Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NeoVac Study).
    Vaccine. 2021 Jul 5. pii: S0264-410X(21)00809.
    >> Share

    June 2021
  59. FENG Y, Yao T, Chang Y, Gao L, et al
    Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial.
    Vaccine. 2021;39:3582-3589.
    >> Share

  60. DIAZ-MITOMA F, Popovic V, Spaans JN
    Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac(R), compared with Engerix-B(R) in healthy Asian adults: A phase 3 randomized clinical trial.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00662.
    >> Share

  61. YANG T, Liu B, Yue L, Xie T, et al
    Preclinical safety assessment of a combined vaccine against Hepatitis a virus and enterovirus 71.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00653.
    >> Share

    May 2021
  62. HIRST A, Hyer RN, Janssen RS
    Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00582.
    >> Share

  63. AWAD AM, Ntoso A, Connaire JJ, Hernandez GT, et al
    An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B(R)) in adults receiving hemodialysis.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00554.
    >> Share

  64. HAN B, Liu W, Du J, Liu H, et al
    Immunogenicity and safety of hepatitis B vaccination in patients with type 2 diabetes in China: An open-label randomized controlled trial.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00540.
    >> Share

  65. HUANG JM, Wang SY, Lai MR, Tseng YK, et al
    Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity.
    Vaccine. 2021 May 7. pii: S0264-410X(21)00485.
    >> Share

  66. TAMANDJOU TCHUEM CR, Andersson MI, Wiysonge CS, Mufenda J, et al
    Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00498.
    >> Share

    April 2021
  67. MARTIN JC, Petrecz ML, Stek JE, Simon JK, et al
    Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA).
    Vaccine. 2021 Apr 15. pii: S0264-410X(21)00345.
    >> Share

  68. YAO T, Shao Z, Wu L, Dong S, et al
    Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: A 3-year follow-up study in China.
    Vaccine. 2021 Apr 2. pii: S0264-410X(21)00378.
    >> Share

    March 2021
  69. EL BARA A, Pivert A, Veillon P, Ng Wing Sang C, et al
    From national HBV and HDV screenings to vaccination and treatment in healthcare workers: The Mauritanian pilot study.
    Vaccine. 2021 Mar 19. pii: S0264-410X(21)00279.
    >> Share

    November 2020
  70. ROSENTHAL EM, Hall EW, Rosenberg ES, Harris A, et al
    Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
    Vaccine. 2020 Nov 4. pii: S0264-410X(20)31387.
    >> Share

    September 2020
  71. ISTRATE A, Azoicai D, Almas A, Radulescu A, et al
    Variable anti-HBs antibody titers in vaccinated birth cohorts - A cross-sectional population-based study.
    Vaccine. 2020 Sep 19. pii: S0264-410X(20)31184.
    >> Share

    July 2020
  72. CELZO F, Buyse H, Welby S, Ibrahimi A, et al
    Safety evaluation of adverse events following vaccination with Havrix, Engerix-B or Twinrix during pregnancy.
    Vaccine. 2020 Jul 30. pii: S0264-410X(20)30970.
    >> Share

    June 2020
  73. YU W, Cao L, Liu Y, Li K, et al
    Two media-reported vaccine events in China from 2013 to 2016: Impact on confidence and vaccine utilization.
    Vaccine. 2020 Jun 30. pii: S0264-410X(20)30632.
    >> Share

    February 2020
  74. ZAHN T, Akhras S, Spengler C, Murra RO, et al
    A new approach for therapeutic vaccination against chronic HBV infections.
    Vaccine. 2020 Feb 26. pii: S0264-410X(20)30291.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016